menu
newsletter
News
2008-11-21Polish biotechnologists and new therapeutics based on coffee compounds
Trigendo Limited company is innovative privately founded Polish biotech company, researching chemical compounds found in coffee that can be used as potential drugs. The company's main focus is on chemical, biochemical and pharmacological research leading to development of new drugs which can bring therapeutic effects in diseases associated with endothelial dysfunction.
2008-11-20Leading pharmaceutical company in the Baltic-Grindeks
reaches 7.65 million lats profit
The financial statements of JSC Grindeks for the first three quarters of the year 2008, submitted to Riga Stock Exchange, certify that the Grindeks Group operated successfully during the first nine months of this year. The net profit during the reporting period was 7.65 million lats, 56.1% more than in the first nine months of 2007. The Group’s turnover during the first nine month amounted to 46.96 million lats, 8.89 million lats or 23.4% more than in the first nine months of 2007.
Ekopol, polish company, has launched a line for
the production of biofuels
Listed on the NewConnect EKOPOL Upper Silesian Holding company has just launched a line for the production of biofuels. As a result, the capacity of manufacturing companies reached to 50 thousand. tonnes of biofuels (with 5-percent. the organic components) per year. New investment was put into service a half month before the planned date. EKOPOL conducted this project of biofuels production in cooperation with other entities.
2008-11-18Antiglaucoma drug Rozalin on the Polish Market
Rozalin is a medicine reducing intraocular pressure in the eye is used to treat glaucoma and ocular high blood pressure. In Poland, for this condition suffer around 800 thousand. people, of which treats every eighth patient. The therapy by Rozalin helps to lower the cost of treatment for patients with this disease by 30 %. in relation to current therapy earlier on the Polish market.
Hungarian pharma Egis to invest EUR 15-20 mln in Turkey
Hungarian listed pharma producer Egis, a major exporter to Russia and the countries of Central and Eastern Europe, is stepping up its marketing efforts in Turkey, which Egis believes could rise to be among the company's top three export destinations. The company intend to invest EUR 15-20 mln.
Financial success of Elstar Oils S.A., polish manufacturer
of biodiesel
Revenues from the sale in October this year of Elstar Oils S.A. in basic activities amounted to 34.9 million USD. For comparison - in September These revenues amounted to EUR 32.7 million (an increase of 2.2 million USD). Cumulative revenues Company in 2008 for the period January-October amount to 376.3 million USD. This amount represents the value of the unit without taking into account revenue from the sale of rape.
2008-11-14New studies on myeloid leukemia treatment in EIT+
in Wroclaw in Poland
A very interesting study has been included in the priorities of the Wroclaw Research Center EIT+ .The team of prof. Eve Marcinkowska will perform in the frame of the "Application of new bionanomaterials in diagnosis and therapy" the project: "Identification of molecular characteristics of the diseases associated with dysfunction of nuclear receptors and its use in the diagnosis”.
2008-11-13Slovenian pharma company as a bright example in times of
financial crisis
Slovenia’s largest pharmaceutical company Krka is expected to report a 16 pct increase in profits in the first nine months.
A successful start-up company in the growing biotech
industry
IMMUNOLAB Comp. Ltd. manufactures and sells a number of different in vitro diagnostics and related services. This polish company was established in 1999 by Prof. Renata Glosnicka with the purpose of transferring the biotechnology research products to commercial utilization.
Euroimplant, polish biotech company, is waiting for money
The biotechnological company listed on the NewConnect is looking for funds for investments. Euroimplant had planned to raise PLN 25m (EUR 6.8m) in its IPO. It managed to raise only PLN 11m. 45 percent of this amount has already been spent.
